Kazia Therapeutics (KZIA) Curent Deferred Tax Liability (2016 - 2017)

Kazia Therapeutics (KZIA) reported Curent Deferred Tax Liability of -$110538.5 for Q4 2017, down 126.57% on a YoY basis from $416045.6 in Q4 2016, and down 126.57% quarter-over-quarter from -$48788.1 in Q4 2016.

Kazia Therapeutics (KZIA) Curent Deferred Tax Liability (2016 - 2017) Analysis & Trends

Kazia Therapeutics has reported Curent Deferred Tax Liability for 2 years, with the latest figure at -$110538.5 in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Kazia Therapeutics 1.70 Bn 1.70 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 -110,538.53
Dec 31, 2017 -110,538.53
Dec 31, 2016 -48,788.05
Dec 31, 2016 -48,788.05